Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Raw Materials (2020 - 2021)

UroGen Pharma (URGN) has disclosed Raw Materials for 2 consecutive years, with $2.4 million as the latest value for Q1 2021.

  • For the quarter ending Q1 2021, Raw Materials changed N/A year-over-year to $2.4 million, compared with a TTM value of $2.4 million through Mar 2021, changed N/A, and an annual FY2020 reading of $1.1 million, changed N/A over the prior year.
  • Raw Materials was $2.4 million for Q1 2021 at UroGen Pharma, up from $1.1 million in the prior quarter.
  • Across five years, Raw Materials topped out at $2.4 million in Q1 2021 and bottomed at $893000.0 in Q2 2020.